166 related articles for article (PubMed ID: 30583814)
1. HBXIP protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Zhou X; Wang X; Duan J; Sun W; Chen Z; Li Q; Ou Z; Jiang G; Ren X; Liu S
Pathol Res Pract; 2019 Feb; 215(2):343-346. PubMed ID: 30583814
[TBL] [Abstract][Full Text] [Related]
2. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
3. BIRC7 and KLF4 expression in benign and malignant lesions of pancreas and their clinicopathological significance.
Yang Z; Li D; Liu Z; Miao X; Yang L; Zou Q; Yuan Y
Cancer Biomark; 2016; 17(4):437-444. PubMed ID: 27802195
[TBL] [Abstract][Full Text] [Related]
4. HBXIP suppression reduces cell proliferation and migration and its overexpression predicts poor prognosis in non-small-cell lung cancer.
Wang Y; Li N; Che S; Jin T; Piao J; Liu S; Lin Z
Tumour Biol; 2017 Jul; 39(7):1010428317709675. PubMed ID: 28718367
[TBL] [Abstract][Full Text] [Related]
5. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
[TBL] [Abstract][Full Text] [Related]
6. Jagged1 and DLL4 expressions in benign and malignant pancreatic lesions and their clinicopathological significance.
Huang SF; Yang ZL; Li DQ; Liu ZY; Wang CW; Miao XY; Zou Q; Yuan Y
Hepatobiliary Pancreat Dis Int; 2016 Dec; 15(6):640-646. PubMed ID: 27919854
[TBL] [Abstract][Full Text] [Related]
7. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z
Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420
[TBL] [Abstract][Full Text] [Related]
8. HBXIP overexpression is correlated with the clinical features and survival outcome of ovarian cancer.
Wang Y; Sun J; Li N; Che S; Jin T; Liu S; Lin Z
J Ovarian Res; 2017 Apr; 10(1):26. PubMed ID: 28388957
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of FZD1 and CAIX are Associated with Invasion, Metastasis, and Poor-Prognosis of the Pancreatic Ductal Adenocarcinoma.
Yang L; Yang Z; Li D; Liu Z; Zou Q; Yuan Y; Xu H
Pathol Oncol Res; 2018 Oct; 24(4):899-906. PubMed ID: 28921449
[TBL] [Abstract][Full Text] [Related]
10. CSN6 expression is associated with pancreatic cancer progression and predicts poor prognosis.
Shi J; Guan X; Zhan F; Liu C; Li Z; Yao Y; Wang B; Lou C; Zhang Y
Cancer Biol Ther; 2019; 20(9):1290-1299. PubMed ID: 31311398
[TBL] [Abstract][Full Text] [Related]
11. Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma.
Yao H; Yang Z; Liu Z; Miao X; Yang L; Li D; Zou Q; Yuan Y
Cancer Biomark; 2016; 17(4):397-404. PubMed ID: 27689616
[TBL] [Abstract][Full Text] [Related]
12. Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.
Zheng J; Huang S; Huang Y; Song L; Yin Y; Kong W; Chen X; Ouyang X
Tumour Biol; 2016 Jun; 37(6):7853-9. PubMed ID: 26695153
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic features and prognostic implications of MYBL2 protein expression in pancreatic ductal adenocarcinoma.
Yu R; Li C; Lin X; Chen Q; Li J; Song L; Lin L; Liu J; Zhang Y; Kong W; Ouyang X; Chen X
Pathol Res Pract; 2017 Aug; 213(8):964-968. PubMed ID: 28559119
[TBL] [Abstract][Full Text] [Related]
14. CLIC1 overexpression is associated with poor prognosis in pancreatic ductal adenocarcinomas.
Jia N; Dong S; Zhao G; Gao H; Li X; Zhang H
J Cancer Res Ther; 2016; 12(2):892-6. PubMed ID: 27461670
[TBL] [Abstract][Full Text] [Related]
15. Paraneoplastic Ma Antigen-Like 1 as a Potential Prognostic Biomarker in Human Pancreatic Ductal Adenocarcinoma.
Kuwae Y; Kakehashi A; Wakasa K; Wei M; Yamano S; Ishii N; Ohsawa M; Wanibuchi H
Pancreas; 2015 Jan; 44(1):106-15. PubMed ID: 25251443
[TBL] [Abstract][Full Text] [Related]
16. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
17. Mortalin expression in pancreatic cancer and its clinical and prognostic significance.
Cui X; Li Z; Piao J; Li J; Li L; Lin Z; Jin A
Hum Pathol; 2017 Jun; 64():171-178. PubMed ID: 28412209
[TBL] [Abstract][Full Text] [Related]
18. AHNAK2 is a potential prognostic biomarker in patients with PDAC.
Lu D; Wang J; Shi X; Yue B; Hao J
Oncotarget; 2017 May; 8(19):31775-31784. PubMed ID: 28423668
[TBL] [Abstract][Full Text] [Related]
19. Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas.
Zhang K; Yao H; Yang Z; Li D; Yang L; Zou Q; Yuan Y; Miao X
Clin Transl Oncol; 2016 Apr; 18(4):352-9. PubMed ID: 26887611
[TBL] [Abstract][Full Text] [Related]
20. Expression of signaling adaptor proteins predicts poor prognosis in pancreatic ductal adenocarcinoma.
Wang L; Lu J; Wu H; Wang L; Liang X; Liang Z; Liu T
Diagn Pathol; 2017 May; 12(1):42. PubMed ID: 28558797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]